"Every day, I got on the scales and I still weighed exactly the same as before," Leith, 85, told U.K. paper 'The Times' ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are looking for stocks to buy and hold for 30 years, here are two no-brainer names ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

An astonishing fact about the GLP-1 meds that are helping millions lose weight: Tirzepatide, the active ingredient in ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

el agonista del GLP-1 de Eli Lilly comercializado como Mounjaro para el tratamiento de la diabetes y Zepbound para la pérdida de peso, afecta los síntomas durante un período de 12 meses. «Se ha ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.